Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) is set to issue its quarterly earnings data on Thursday, August 10th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.08. Aurinia Pharmaceuticals had a negative net margin of 48,278.23% and a negative return on equity of 50.53%. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. On average, analysts expect Aurinia Pharmaceuticals to post $-1.07 EPS for the current fiscal year and $-0.61 EPS for the next fiscal year.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded down 0.9772% on Monday, reaching $6.0899. The company had a trading volume of 161,089 shares. The company’s 50-day moving average is $6.38 and its 200-day moving average is $6.03. Aurinia Pharmaceuticals Inc has a 52-week low of $1.74 and a 52-week high of $10.54. The company’s market capitalization is $507.12 million.

A number of analysts have commented on AUPH shares. Cantor Fitzgerald reiterated a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, April 21st. HC Wainwright decreased their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 18th. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. FBR & Co reiterated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, April 11th. Finally, Vetr cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price target for the company. in a report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $9.28.

TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with's FREE daily email newsletter.